Member Login

              Click here if you forgot your password.

Current Events

Qualified Person Education Course Module A - Live Online Training

29/30 November 2023
Live Online

EQPA Members Area

IMP Working Group Members Area

Document and track your personal development - with the Continuous Professional Development (CPD) Documentation Template

To access the template for documenting and tracking your past and ongoing activities, please go here.

After filling out the form, you will be able to create and print out a PDF file.

Brexit: Importation of IMPs from approved countries in a no deal scenario


The MHRA recently provided guidance on how the management and oversight of the import of investigational medicinal products (IMPs) from listed countries will work in a no deal scenario. If the UK leaves the EU without an agreement, sponsors of UK clinical trials that source IMPs from an EEA State will need to review their existing supply chains.

As reported before in Clinical Trials if there is no Brexit Deal, a sponsor of a UK clinical trial using IMPs imported from countries on an ‘approved country for import’ list (initially, all EU and EEA countries) will require a UK Manufacturing and Import Authorization (MIA(IMP)) holder to put in place an assurance system to check these IMPs have been certified by a Qualified Person (QP) in a listed country, before release to the trial. However, IMPs that have been QP certified in a listed country will not require recertification in the UK.

The MHRA guidance on importation of investigational medicinal products from approved countries is to describe the principles for the management and oversight of the import of IMPs to the UK from listed countries. In addition, there will be a one-year transition period following the date of the UK’s exit from the EU to implement this guidance.


Conference Recommendations